Core Points - A securities class action lawsuit has been filed against Zenas BioPharma, Inc. alleging misleading statements related to its September 2024 IPO [1][4] - The lawsuit claims that Zenas overstated its financial runway, projecting 24 months of available capital, while later admitting it could only fund operations for 12 months [4] - Following the disclosure of its financial situation, ZBIO shares fell nearly 49%, closing at $8.72 on April 15, 2025 [4] Allegations in the Complaint - The lawsuit was filed in the U.S. District Court for the District of Massachusetts [4] - Zenas BioPharma and several underwriters are accused of providing inaccurate financial information in their IPO registration materials [4] - The significant drop in share price indicates the potential impact of the alleged misleading statements on investors [4] Importance of Lead Plaintiff Status - The lead plaintiff represents all class members and directs the litigation, including case strategy and settlement discussions [5] - Investors with substantial losses often seek this role to ensure vigorous prosecution of the case [5] Cohen Milstein's Track Record - Cohen Milstein is recognized as a leading plaintiffs' securities firm in the U.S., noted for high-impact securities class actions [6] - The firm has a history of successful outcomes, including a $1 billion settlement in the In re Wells Fargo Securities Litigation [6]
Cohen Milstein Continues Lead Plaintiff Search for Zenas BioPharma (ZBIO) Securities Fraud Class Action Following Post-IPO Stock Decline